Skip to main content

Table 2 Weight, cholesterol, average plasma non-fasting glucose and HbA1c levels

From: Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice

  Group Weight (g) Cholesterol HDL-C LDL-C Average non-fast glucose HbA1c
(mg/dl) (mg/dl) (mg/dl) (mg/dl) (%) (mmol/L)
apoE -/- DM Control (n = 12) 28.11±1.40 1082.46±137.40 113.30±15.47 767.10±45.40 547.99±36.85 9.10±0.45 76.00 ± 4.93
  Alum (n = 12) 28.64±2.53 1072.06±144.53 136.12±23.20 752.57±55.88 557.63±29.55 8.76±0.40 72.13 ± 4.29
  Alum + AGE-LDL (n = 12) 28.17±2.43 1084.85±138.43 151.97±25.08* 739.37±44.92 548.53±44.33 8.58±0.43 70.25 ± 4.56
LDLR -/- DM Control (n = 10) 27.11±1.35 1077.65±115.22 127.11±21.33 781.86±44.43 531.51±42.40 8.72±0.16 71.88 ± 1.73
  Alum (n = 10) 28.03±2.11 1085.10±154.39 138.44±20.42 778.58±33.78 548.52±51.53 8.67±0.17 71.38 ± 1.85
  Alum + AGE-LDL (n = 10) 28.21±1.03 1090.24±143.53 153.91±21.14* 768.55±44.97 536.35±42.65 8.52±0.13 69.88 ± 1.55
  P value n.s. n.s.   n.s. n.s. n.s. n.s.
  1. Mean values and standard deviations are shown. *p < 0.05 vs. PBS control.